home / stock / prvb / prvb news

PRVB News and Press, Provention Bio Inc. From 06/09/19

Stock Information
Company Name: Provention Bio Inc.
Stock Symbol: PRVB
Market: NASDAQ
Website: proventionbio.com
Menu
PRVB PRVB Quote PRVB Short PRVB News PRVB Articles PRVB Message Board
Get PRVB Alerts

News, Short Squeeze, Breakout and More Instantly...
PRVB - A Single Course of Provention's PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least Two Years

OLDWICK, N.J. , June 9, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that results from the National Institutes of Health (NIH)-sponsored "At-Risk" Study...
PRVB - Provention Bio reports Q1 results

Provention Bio (NASDAQ: PRVB ): Q1 GAAP EPS of -$0.29. More news on: Provention Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

PRVB - Provention Bio Reports First Quarter 2019 Financial Results

OLDWICK, N.J. , May 8, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2019 and provided a ...

PRVB - Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis

OLDWICK, N.J. , May 8, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced preliminary top-line results from its Phase 1b PULSE study which evaluated ...
PRVB - ROAN, SOHU, CYOU and GDI among notable midday movers

Gainers:  Roan Resources (NYSE: ROAN ) +41% . Alterity Therapeutics (NASDAQ: ATHE ) +32% . Changyou.com (NASDAQ: CYOU ) +22% . Sohu.com (NASDAQ: SOHU ) +19% . Enlivex Therapeutics (NASDAQ: ENLV ) +19% . Gardner Denver Holdings (NYSE: GDI ) +16% . Provention Bio (NASDAQ: PRVB ) ...

PRVB - Provention Bio Completes Enrollment of Phase 2a PRINCE Clinical Trial with PRV-6527 in Patients with Moderate to Severe Crohn's Disease

OLDWICK, N.J. , April 24, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has completed the enrollment in its Phase 2a PRINCE (PRovention In...

PRVB - FARO, HOLI, ZGNX and FIXX among notable midday movers

Gainers: ATA (NASDAQ: ATAI ) +97% . Provention Bio (NASDAQ: PRVB ) +29% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +24% . Chimerix (NASDAQ: CMRX ) +22% . FARO Technologies (NASDAQ: FARO ) +17% . Soliton (NASDAQ: SOLY ) +15% . GEE Group (NYSEMKT: JOB ) +14% . Geron (NASDAQ: GERN ) ...
PRVB - Provention Bio commences late-stage study of T1D candidate teplizumab

Dosing is underway in a Phase 3 clinical trial, PROTECT , evaluating Provention Bio's (NASDAQ: PRVB ) PRV-031 (teplizumab) in patients with recent-onset type 1 diabetes (T1D). More news on: Provention Bio, Inc., Healthcare stocks news, Read more ...

PRVB - Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes

OLDWICK, N.J. , April 9, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has dosed the first patient in its Phase 3 PROTECT clinical trial o...

PRVB - Provention Bio Announces Key Additions to its Senior Management Team

OLDWICK, N.J. , April 2, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Douglas Jacobstein , M.D., as Vice President of Clinica...
Previous 10 Next 10